UPCC 13418: A Multicenter Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination with Gilteritinib in Subjects with Relapsed/Refractory Acute Myeloid Leukemia
Enrolling By Invitation
99 years or below
All
Phase
1
20 participants needed
1 Location
Brief description of study
The purposes of this study are to see if the study drugs, venetoclax and gilteritinib can be safely and effectively combined for the treatment of patients with acute myeloid leukemia (AML) that has returned after prior treatment, or has failed to respond to prior treatment and identify potential biomarkers.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: leukemia
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 830197
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
